Harvard obtains manufacturing and selling rights and Cellectis receives upfront and milestones fees while retaining certain rights

Paris (France) and Holliston (Massachusetts, USA), – Cellectis (Alternext: ALCLS), the French genome engineering specialist, and Harvard Apparatus, a division of Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, have announced today that they have signed a license agreement that grants Harvard Apparatus the worldwide exclusive right to manufacture and sell, for research use, the full line of electroporation-based instruments acquired by Cellectis from CytoPulse in

September of 2010. Cellectis retains all rights to the use of these products for its own research and development programs as well as in clinical trials and prophylactic or therapeutic procedures, for both humans and animals.

In the agreement, Cellectis will receive a payment of $1.3M from Harvard Apparatus. Cellectis will retain some annual licensing fees owed by existing and new customers. The CytoPulse instruments involved include DermaVax, OncoVet, Hybrimune, Cyto-LVT-S and Cyto-LVT-P.

“We are delighted to work with Harvard Apparatus on the distribution of this very efficient technology”, declared Dirk Pollet, Chief Business Officer for Cellectis. “This deal provides Harvard Apparatus with an excellent new product line, while generating a robust revenue stream for Cellectis. In addition, it allows the technology to be made available to the research community to explore its

potential.”

Chane Graziano, CEO of Harvard Bioscience, commented, “This license significantly expands the cell biology research product line offered by Harvard Apparatus under the Warner Instruments and BTX brands. The technology is quite unique and patent protected and will provide our research customers with new tools to perform their electroporation and electrofusion experiments.”

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets

innovative tools:meganucleases. These molecular scissors enable targeted modifications to DNA,

with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more

than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies

across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or

pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in

Paris and has secured over €70 million in funding since inception.

More information at www.cellectis.com

About Harvard Apparatus

Harvard Bioscience (“HBIO”) is a global developer, manufacturer and marketer of a broad range of

specialized products, primarily apparatus and scientific instruments, used to advance life science

research and regenerative medicine. HBIO sells its products to thousands of researchers in over

100 countries primarily through its 850 page catalog (and various other specialty catalogs), its

website, through distributors, including GE Healthcare, Thermo Fisher Scientific and VWR, and via

our field sales organization. HBIO has sales and manufacturing operations in the United States, the

United Kingdom, Germany and Spain with additional facilities in France and Canada. For more

information, please visit www.harvardbioscience.com